RemeGen荣昌生物 Alternatives & Competitors
12 companies similar to RemeGen荣昌生物 — 用科学提高生命质量
Companies similar to RemeGen荣昌生物
TORL BioTherapeutics LLC
Advancing novel antibody-based therapies to transform the lives of cancer patients.
Vyriad
Vyriad is a clinical-stage biotech company developing targeted genetic therapies that deli...
Io Therapeutics
Io therapeutics focuses on developing drugs that target nuclear receptors in order to trea...
Sutro Biopharma, Inc.
Changing the future of Oncology
Rival Readout
Competing with RemeGen荣昌生物? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Century Therapeutics, Inc
Advancing iPSC-derived cell therapies to transform care in autoimmune disease and cancer
Asieris Pharmaceuticals
We strive for healthy and dignified lives!
Kestrel Therapeutics
We aspire to invent brilliant technologies for difficult cancer targets, beginning with mu...
Biond Biologics Ltd
Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics f...
SFA Therapeutics
A New Paradigm in Drug Development
Yuanyin Bio
Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clini...
Therabene
Pioneering PROTAC Molecules for Cancer and Autoimmune Disease Treatment with Collaborative...
About RemeGen荣昌生物
RemeGen荣昌生物 is positioning itself as a trailblazer in the biotech industry with its innovative approach to biologic medicines. Founded in 2008, this Chinese biotech firm is focused on transforming the treatment landscape for cancer, autoimmune, and eye diseases by pioneering biologics. With a mission encapsulated i...
Drug Discovery, Research and Development, Biological Medicine Manufacturing, Clinical Trial Conducting, New Drug Market Launch
Patients with Major Diseases, Healthcare Providers, Medical Institutions, Pharmaceutical Distributors
Biologics, Biotech Innovation, Therapeutic Innovation, Cancer Treatment, Autoimmune Disease Therapy, Eye Disease Treatment, Biopharmaceutical Industry, ADC (Antibody-Drug Conjugates), Biological Drugs, Clinical Studies, Drug Development, Unmet Clinical Needs, Global Commercialization, Scientific Research Investment, Differentiated Drugs
B2B, B2C, D2C
Product Sales, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around RemeGen荣昌生物: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at RemeGen荣昌生物 on 11 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.